LINCOTEK
Global contract manufacturer Lincotek announced today that it has signed an agreement to acquire a majority stake in Italy-based Pegasus’ medical division. The Alaria family will remain fully involved in the business, with Alberto Alaria taking the position of Managing Director of the new entity.
The move will further strengthen the Medical Division of Lincotek Group , which is continuing its global investment program to respond to ever-more demanding customer requirements in terms of integrated solutions. Through new technologies and automation, the company is addressing the growing interest of the orthopedic device market in an automated forging service, increasing efficiency along the supply chain, setting new standards around quality and reliability and further reducing lead time.
The investment represents an important addition to an already comprehensive set of capabilities that Lincotek Medical has in-house and enhances the company’s competitive edge, adding unique, state-of- the-art capabilities in the forging field.
Established in 2007 in Torino, northern Italy, Pegasus decided in 2019 to expand its innovative forging processes into the medical market. The brand-new facility - with a surface area of around 3,000 sqm - is completely dedicated to orthopedic applications, being ISO 13485 certified and having an ISO 17025 certified internal laboratory. Lincotek’s forging offers a unique level of automation through the manufacturing process ensuring state-of-the-art product quality, total process control and repeatability.
The fully robotized forging line - which allows the manufacture of high-quality forged implantable parts to customer specifications – is the flagship of a complete production service of forged components. Its capabilities are combined with a state-of-the-art, AMS-2750-compliant heat treatment furnace ; automated pickling line and liquid penetrant inspection unit ; laboratory equipment; internal mold manufacturing; robotized deburring and polishing unit; and computerized dimensional control.
Lincotek Medical will therefore offer a new, impressive, high-volume capacity, through single service or fully-integrated solutions to support OEMs with a strategic long-term partnership.
Winfried Schaller, CEO of Lincotek Group commented: “With the acquisition of the majority stake in Pegasus medical division, Lincotek Medical is in a stronger position than ever before to support orthopedic OEMs. By combining this impressive forging service with our existing offering, we are able to help customers stay competitive and get to market even faster. It really is a new world of advanced automation and productivity.”
Speaking for Pegasus, Alberto Alaria, the company’s Managing Director, said: “Pegasus is proud to enter into partnership with Lincotek Group which represents a great opportunity to grow our presence in the forged medical implants market with the offering of high-quality products. The new synergies and product integration that will be generated moves us a step ahead and creates the possibility of further strengthening the cooperation with our valued customers.”
Bringing this full suite of processes in-house, orthopedic OEMs can now rely on a well-established partner, which has broad capabilities and brings together the core competencies of R&D, product design, regulatory affairs, and manufacturing all under one roof, keeping focus on their core competencies.
About Lincotek
Lincotek, headquartered in Rubbiano, Parma - Italy, is a global contract manufacturer for services in niche markets including Industrial Gas Turbines, Aviation and Medical Device applications, as well as a leading manufacturer of industrial coating equipment and one of the most respected producers in the Additive Manufacturing field. The Group is family-owned and has more than 1,300 employees located in 17 production facilities across Europe, North America and Asia.
About Pegasus
Established in Favria, Torino (Italy) in 2007 on a 100,000 sqm site, of which 20,000 is covered, PEGASUS has forging, heat treating, machining and NDT inspection capabilities for the production of forged and rolled components for Industrial and Medical purposes.
For more information, please visit lincotek.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005021/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom